"As many patients with tardive dyskinesia are also managing a mood disorder, it is important to provide them with a treatment option that has demonstrated to be effective, is well-tolerated and does not impact the management of their underlying psychiatric condition," said Eiry W. Roberts, M.D., Chief Medical Officer at
Poster presentations include new long-term data analyses examining the effects of INGREZZA in adult patients with TD, including: evaluating INGREZZA in TD patients taking concomitant medications for psychiatric conditions; the effects of long-term treatment with INGREZZA in adults with TD and a primary mood disorder; and new data from RE-KINECT on the correlation between uncontrollable movements assessments as reported by patients, caregivers and healthcare providers.
The six Neurocrine-sponsored abstracts that will be presented at the 2018 Annual
Poster Presentation Sessions
- Effects of Long-Term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder
Abstract 141, Poster Session,Friday, Oct. 26 ,1:30-2:30 p.m. ET - Tardive Dyskinesia Symptom Screening in Real-World Outpatient Settings: Correlations between Patient-, Caregiver-, and Clinician-Reported Assessments in the RE-KINECT Study
Abstract 101, Poster Session,Friday, Oct. 26 ,1:30-2:30 p.m. ET - Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials
Abstract 224, Poster Session,Friday, Oct. 26 ,5:30-7:30 p.m. ET - Long-Term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia
Abstract 226, Poster Session,Friday, Oct. 26 ,1:30-2:30 p.m. ET - Valbenazine Treatment of Tardive Dyskinesia in Patients with Intellectual Disability: A Case Series
Abstract 114, Poster Session,Friday, Oct. 26 ,5:30-7:30 p.m. ET - A Modified Delphi Consensus Approach to Clinical Opinions on Tardive Dyskinesia Abstract 225, Poster Session,
Friday, Oct. 26 ,1:30-2:30 p.m. ET
About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. The condition is caused by prolonged use of treatments that block dopamine receptors in the brain, such as antipsychotics commonly prescribed to treat mental illnesses such as schizophrenia, bipolar disorder and depression and certain anti-nausea medications. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect at least 500,000 people in the U.S.
About INGREZZA® (valbenazine) capsules
INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first FDA-approved product indicated for the treatment of adults with tardive dyskinesia, a condition associated with uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.
INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed in Neurocrine's laboratories, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.
Important Safety Information
Contraindications
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.
Warnings & Precautions
Somnolence
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.
QT Prolongation
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
Adverse Reactions
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-
Please see INGREZZA full Prescribing Information at www.INGREZZAHCP.com
About Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from INGREZZA and the continued success of the launch of INGREZZA. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: the Company's future financial and operating performance; risks and uncertainties associated with the commercialization of INGREZZA, including the likelihood of continued revenue and prescription growth of INGREZZA; risks and uncertainties relating to factors that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that the
View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-data-analyses-on-the-long-term-effects-of-ingrezza-valbenazine-in-tardive-dyskinesia-patients-with-mood-disorders-at-the-2018-annual-psych-congress-300736413.html
SOURCE
Neurocrine Biosciences, Inc., Navjot Rai (Media & Investors), 858-617-7623, IR@neurocrine.com